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Abstract Research evaluating the relationship of comor-
bidity to treatment outcome for panic disorder has
produced mixed results. The current study examined the
relationship of comorbid depression and anxiety to
treatment outcome in a large-scale, multi-site clinical
trial for cognitive-behavior therapy (CBT) for panic
disorder. Comorbidity was associated with more severe
panic disorder symptoms, although comorbid diagnoses
were not associated with treatment response. Comorbid
generalized anxiety disorder (GAD) and major depressive
disorder (MDD) were not associated with differential
improvement on a measure of panic disorder severity,
although only rates of comorbid GAD were significantly
lower at posttreatment. Treatment responders showed
greater reductions on measures of anxiety and depressive
symptoms. These data suggest that comorbid anxiety and
depression are not an impediment to treatment response,
and successful treatment of panic disorder is associated
with reductions of comorbid anxiety and depressive
symptoms. Implications for treatment specificity and
conceptual understandings of comorbidity are discussed.
Keywords Panic disorder . Comorbidity .
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Psychiatric comorbidity is typically defined as the co-
occurrence of two or more psychiatric disorders within the
same individual (Maser and Cloninger 1990). Comorbidity
research is particularly important because the majority of
individuals presenting for treatment for an Axis I anxiety or
mood disorder have at least one additional anxiety or mood
disorder diagnosis (e.g., Brown et al. 1995; Brown and
Barlow 1992, 1995; de Ruiter et al. 1989; Sanderson et al.
1990). For individuals seeking treatment for panic disorder,
comorbidity rates for Axis I disorders generally range from
51% to 69% with some of the larger studies suggesting that
estimates are approximately 60%, with generalized anxiety
disorder (GAD), social phobia, and depression being the
most frequently assigned disorders (Brown and Barlow
1992; Brown et al. 1995, 2001a; Sanderson et al. 1990;
Tsao et al. 1998, 2002).
Studies examining treatment outcome for panic disorder
with anxiety and depression comorbidity have produced
mixed results. While a number of studies have suggested
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that the presence of comorbid diagnoses, particularly
depression, is associated with less improvement on some
measures of panic symptoms (i.e., achieving substantial
improvement in panic symptoms or attaining “panic-free”
status) (Brown et al. 1995; Steketee et al. 2001; Tsao et al.
1998), these findings have not been consistent. For
example, Tsao et al. (2002) found no differences between
anxious and depressive comorbid and non-comorbid groups
at posttreatment on panic severity, agoraphobia severity,
and endstate functioning, and similar findings have been
evident when examining comorbid depression, specifically
(McLean et al. 1998). In fact, some comorbidity, such as
social phobia, may be associated with better treatment
outcome for panic disorder (Brown et al. 1995). The mixed
outcomes from these studies suggest that no stable
relationship between certain types of comorbidity and panic
disorder treatment has yet emerged. This may be due in part
to variability in assessment measures, as well as the
relatively small sample sizes in previous studies (e.g., Tsao
et al. 1998, 2002).
A more consistent and encouraging finding is that,
overall, comorbid diagnoses show significant reductions
over the course of treatment, even though these concerns
are not the focus of the treatment provided. With the
exception of one study (McLean et al. 1998) that found
depressive symptoms changed only at a rate similar to
changes expected from the passage of time, results from
Brown et al. (1995) and two other studies (Tsao et al.
1998, 2002) report significant reductions in the rates of
comorbid GAD, social phobia, and depression from pre-
to posttreatment.
The current study aims to replicate and extend the
research on comorbidity in panic disorder by examining
the relationship of comorbid anxiety and unipolar mood
disorders to treatment outcome. The strengths of this
study include (a) a large sample size generated from four
study sites, (b) both clinician-rated and self-report
measures focusing on panic and associated symptoms,
(c) carefully monitored adherence to a manualized CBT
protocol for panic disorder, and (d) diagnostic assess-
ments conducted by independent evaluators (IEs). Al-
though the panic disorder and comorbidity literature has
not produced consistent findings upon which to base
hypotheses, given the data from relatively large samples
in previous studies, we hypothesize that rates of
comorbidity will approximate those previously reported
in studies where panic disorder is the principal diagnosis,
with GAD, social phobia, and major depressive disorder
(MDD) being the most common comorbid diagnoses.
Furthermore, we hypothesize that comorbidity will not
be associated with a decreased likelihood of achieving
treatment response, and overall rates of comorbid
diagnoses will decrease following treatment.
Method
Participants
Participants were 454 patients who were part of a multi-site,
large-scale clinical trial examining long-term treatment
strategies for panic disorder (see Aaronson et al. 2008 for
full description of study procedures). Of this sample, 379
were enrolled in the study at four different sites: 93 at the
Center for Anxiety and Related Disorders at Boston
University, 92 at the Hillside Hospital of the North Shore/
Long Island Jewish Health Care System, 103 at the Western
Psychiatric Institute and Clinic, and 91 at Yale University.
Subsequently, 256 patients completed the acute phase of the
study and received a posttreatment diagnostic interview and
assessment; 123 patients either dropped out or were
removed from the study.
Inclusion criteria were: (a) a principalDSM-IV diagnosis of
panic disorder with or without agoraphobia; (b) age 18 years
or older; (c) no substance abuse or dependence within the last
6 months; (d) absence of active suicide potential within the
last 6 months; (e) absence of any history of psychosis, bipolar
I disorder, bipolar II disorder, or cyclothymia; (f) no current
application pending or existing for a medical disability claim;
(g) no significant cognitive impairment; (h) free from current
uncontrolled general medical illness requiring intervention; (i)
absence of concurrent psychotherapeutic treatment directed at
anxiety and panic disorders and; (j) no concurrent psycho-
pharmacological treatment that may have anti-panic effects
(participants were required to taper medication by session 9).
Informed consent was obtained from all participants prior to
study enrollment. This study was approved by the institu-
tional review boards at all four study sites.
Demographic information for treatment completers is
available in Table 1. There were no gender or ethnicity
differences between individuals who did and did not
complete treatment. However, treatment completers were
significantly older (M=38.4, SD=11.7) than noncompleters
(M=34.6, SD=11.6), t(379)=−3.00, p=0.003. Treatment
completers also attended significantly more years of school
(M=15.3, SD=3.0) than noncompleters (M=14.3, SD=2.7),
t(372)=−2.94, p=0.004.
Measures
ADIS-Lite The Anxiety Disorders Interview Schedule-Lite
(ADIS-Lite) is an adaptation of the ADIS for DSM-IV-
Lifetime version (ADIS-IV-L; Di Nardo et al. 1994) and
differs only with respect to assessing for the presence of
symptoms (yes/no) rather than a dimensional rating for all
symptoms (0–8 scale). This semi-structured clinical inter-
view focuses on the anxiety, mood, substance use, and
somatoform disorders and the ADIS-IV-L has demonstrated
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excellent to acceptable interrater reliability for the anxiety
and mood disorders (Brown et al. 2001b).
IEs across the four sites underwent a rigorous
certification procedure to ensure standardization of
administration and diagnostic reliability, and were blind
to participants’ progress. Ten percent of all assessments
were randomly selected for diagnostic co-rating. Intra-
class correlation coefficients were calculated to assess
interrater reliability, which was acceptable to excellent
across the diagnoses (panic disorder ρI=0.885, agoraphobia
ρI=0.658, MDD ρI=0.99, GAD ρI=0.999, obsessive–
compulsive disorder ρI=0.747, social phobia ρI=0.909,
specific phobia ρI=0.795, dysthymia ρI=0.489, and
posttraumatic stress disorder ρI=0.486).
Agoraphobia Scale IEs rated panic-related fear and avoid-
ance of particular situations, ranging from 0 (no fear/never
avoids) to 4 (extreme fear/always avoids). This measure has
demonstrated excellent internal consistency (α=0.87 in our
sample) and is associated with excellent interrater reliability
(r=0.86, Brown et al. 2001b).
Panic Disorder Severity Scale—Independent Evaluator
Version (PDSS-IE; Shear et al. 1992, 1997) The PDSS-IE
is a 7-item measure for assessing the frequency, distress,
and avoidance caused by panic attacks. Each item is
rated on a 0 (none/mild) to 4 (extreme/severe) scale.
Interrater reliability (N=434, ρI=0.993) and internal
consistency (α=0.81) were both excellent in the current
study.
Structured Interview Guide for the Hamilton Anxiety Rating
Scale and Structured Interview Guide for the Hamilton
Depression Rating Scale (SIGH-A and SIGH-D) (Shear et al.
2001; Williams 1988) The SIGH-A and SIGH-D were
developed to create a structured format for administering
the Hamilton Anxiety Rating Scale (Hamilton 1959) and
Hamilton Rating Scale for Depression (Hamilton 1960),
respectively. The SIGH-A and SIGH-D have each demon-
strated good inter-rater and test–retest reliability. In the
current study, the SIGH-A demonstrated excellent interrater
reliability and internal consistency (N=193, ρI=0.990,
α=0.86), as did the SIGH-D (N=181, ρI=0.997, α=0.84).
Anxiety Sensitivity Index (ASI; Peterson and Reiss 1987)
The ASI is a 16-item self-report scale used to evaluate
anxiety focused on panic-related bodily sensations. It has
been used extensively in research on panic disorder and
demonstrated excellent internal consistency (α=0.88) in
our sample.
Work and Social Adjustment Scale (WSAS; a modification
of a scale introduced by Hafner and Marks 1976) The
WSAS is a five-item measure that asks participants to rate
the degree of interference caused by their symptoms in five
life domains on a 0 (no interference) to 8 (very severe
interference) scale. This measure has shown adequate test–
retest reliability (r=0.73) (Mundt et al. 2002) and good
internal consistency (α=0.80) in our sample.
Measures of Treatment Response
Criteria for treatment responder status were set as part of
the larger clinical trial (Aaronson et al. 2008). Criteria for
treatment response were: (a) receive a score of “2” (much
improved) or “1” (very much improved) on the Clinical
Global Impressions scale (CGI; Guy 1976), as determined
by the IE at the posttreatment assessment and (b) evidence
at least a 40% reduction in the PDSS-IE score from
pretreatment. We also included an additional, more strin-
gent measure of functioning: panic-free status (i.e., having
no full or limited symptom panic attacks in the past month),
as used in the Brown et al. (1995) study. The first question
of the PDSS-IE assessed for the presence of any panic
attacks in the past month.
Procedure
The acute study phase consisted of eleven individual
sessions of CBT for panic disorder that was delivered via
a manualized protocol (a modified version of the standard
Panic Control Treatment; Barlow and Craske 2007). Follow-
ing treatment, participants were then randomized to additional
arms of the study (reports are in preparation). Responders
were randomized to receive either (a) no additional treatment
Table 1 Demographic information for treatment-completing sample
(N=256)
Measure Number (%)
Age (mean) 38.37
Women 165 (64.5)
Ethnicity
Caucasian 224 (87.5)
African–American 14 (5.5)
Asian or Pacific Islander 14 (5.5)
American Indian or Alaskan Native 3 (1.2)
Other 1 (0.4)
Marital status
Never married 93 (36.3)
Married 134 (52.4)
Separated or divorced 28 (10.9)
Number of children (mean) 1.14
Years attended school (mean) 15.25
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or (b) nine monthly maintenance CBT sessions; all were
followed for a total of 21 months posttreatment. Non-
responders were randomized to receive either (a) an
additional course of CBT for panic disorder (3 months) or
(b) a trial of paroxetine (lasting from 3–12 months) and
participants in each nonresponder group were followed for
12 months total. Due to the addition of different treatments
following post-acute CBT sessions, the current paper focuses
only on the acute phase of treatment where all participants
received CBT.
Data Analyses
All patients who completed acute treatment were included
in analyses (N=256). Intent-to-treat analyses were not
conducted, given that the measures used were administered
only at pre- and posttreatment. For all data analyses, a
modified Bonferroni adjustment was applied to control for
Type I error based on the number of pretreatment
comparisons. Twenty-four pretreatment comparisons were
conducted (24 t-tests and 4 correlations), such that analyses
resulting in a significance value of 0.0021 or less were
considered significant (0.05/24 = 0.0021). This criterion
was then applied to all analyses to determine significance.
Results
Analyses were first conducted to examine pretreatment
differences in rates of comorbidity between treatment
completers and noncompleters (see Table 2). No significant
differences were found. A detailed paper of study attrition is
currently under review (White et al. 2009, Attrition in a
multi-center clinical trial for panic disorder. Unpublished
manuscript). Of treatment completers, those with comorbid-
ity (M=40.3, SD=11.9) were significantly older (M=36.8,
SD=11.2) than those without comorbidity t(254)=−2.44,
p<0.5. The same was true for those with (M=40.3, SD=
11.9) and without (M=40.3, SD=11.9) comorbid GAD, and
with (M=40.3, SD=11.9) and without (M=40.3, SD=11.9)
comorbid specific phobia. Age was not significantly associ-
ated with any other comorbid diagnosis or measure of panic
disorder severity.
Rates of Comorbidity at Pretreatment
Table 2 describes the pattern of comorbidity in the
treatment completing sample (N=256). Of note, the rate
of comorbid MDD appears slightly low, given rates
reported in other large-scale studies, e.g., Brown et al.
(2001a) reported that of patients with principal panic
disorder, 31% also had a comorbid mood disorder.
However, the rate of MDD reported in the current study is
similar to those reported in other studies focusing solely on
the principal diagnosis of panic disorder: 12.7% (Brown et
al. 1995) and 21.2% (Tsao et al. 1998).
Severity of Panic Symptoms at Pretreatment
The presence of at least one comorbid diagnosis was
associated with greater severity on all four measures of panic
disorder and agoraphobia symptoms, as shown in Table 3.
Regarding the most common comorbid diagnoses, individ-
uals with comorbid GAD at pretreatment reported higher
PDSS-IE scores t(254)=−3.44, p<0.001, d=0.48 and ASI
scores t(254)=−3.32, p<0.001, d=0.47. Comorbid social
Pretreatment variable Completers (n=256) Noncompleters (n=123)
Number (%) of patients Number (%) of patients
Any comorbidity 117 (45.7%) 68 (55.3%)
Any Anxiety 99 (38.7%) 60 (48.9%)
Any depression 48 (18.8%) 24 (19.5%)
GAD 65 (25.4%) 39 (31.7%)
MDD 42 (16.4%) 20 (16.3%)
Specific phobia 30 (11.7%) 22 (17.9%)
Social phobia 28 (10.9%) 20 (16.3%)
OCD 15 (5.9%) 5 (4.1%)
PTSD 10 (3.9%) 11 (8.9%)
Hypochondriasis 9 (3.5%) 6 (4.9%)
Dysthymia 8 (3.1%) 5 (4.1%)
1 comorbid diagnosis 58 (22.7%) 25 (20.3%)
2 comorbid diagnoses 38 (14.8%) 31 (25.2%)
3 comorbid diagnoses 14 (5.5%) 8 (6.5%)
4 or more comorbid diagnoses 7 (2.7%) 4 (3.3%)
Table 2 Rates of pretreatment
comorbidity for treatment
completers and noncompleters
GAD generalized anxiety
disorder; MDD major depressive
disorder; OCD obsessive–
compulsive disorder; PTSD
posttraumatic stress disorder.
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phobia at pretreatment was associated with higher ASI scores
t(254)=−3.14, p<0.002, d=0.62. Comorbid MDD was also
associated with significantly greater panic disorder severity
across all measures: PDSS-IE, t(254)=−6.67, p<0.001,
d=1.04, Agoraphobia Scale, t(52.31, adjusted for unequal
variances)=−3.98, p<0.001, d=0.74, ASI, t(254)=−3.65,
p<0.001, d=0.60, and WSAS, t(254)=−6.14, p<0.001,
d=0.97. Number of comorbid diagnoses at pretreatment
was significantly correlated to PDSS-IE scores (r=0.37,
p<0.001), Agoraphobia Scale scores (r=0.24, p<0.001),
ASI scores (r=0.31, p<0.001), and WSAS scores (r=0.26,
p<0.001). No significant differences on pretreatment meas-
ures of panic disorder were found for individuals with
comorbid specific phobia at pretreatment.
Pretreatment Comorbidity and Treatment Response
The most common comorbid diagnoses at pretreatment were
compared to measures of treatment outcome (i.e., treatment
responder/nonresponder, panic-free/not panic-free). GAD,
MDD, social phobia, or specific phobia at pretreatment was
not associated with differential rates of treatment response or
individuals achieving panic-free status.
Comorbid Anxiety and Depression and Changes in Panic
Symptoms Across Treatment
Two (comorbidity: present v. absent) × 2 (time: pre v. post)
repeated measures ANOVAs were conducted across PDSS-IE
scores for each of the most common comorbid anxiety and
depressive disorders (GAD and MDD). For participants with
and without comorbid GAD, a significant time effect was
found F(1, 254)=393.74, p<0.001, h2p ¼ 0:61. However,
there were no significant group or interaction effects on this
variable (h2p ¼ 0:04 and 0:01, respectively). For those with
and without comorbid MDD, analysis of the PDSS-IE
revealed a significant effect of time F(1, 254)=333.48, p<
0.001, h2p ¼ 0:57 and group F(1, 254)=34.87, p<0.001,
h2p ¼ 0:12; however, no significant group x time interac-
tion effect emerged (h2p ¼ 0:03).
The large sample size of this study allowed additional
analyses to be conducted by separating participants into four
groups: no comorbid diagnosis of any kind (n=139), only
anxiety comorbidity (including individuals with any comor-
bid anxiety disorder such as GAD, social phobia, specific
phobia, OCD, PTSD, etc.; n=67), only depressive comor-
bidity (including MDD and dysthymia; n=16), and both
comorbid anxiety and depression (n=32). Two participants
had only a comorbid diagnosis that was not an anxiety or
depressive disorder (e.g., hypochondriasis) and were exclud-
ed from these analyses. Results revealed a significant effect
of time F(1, 250)=328.62, p<0.001, h2p ¼ 0:57 and group F
(3, 250)=15.03, p<0.001, h2p ¼ 0:15, although, no signifi-
cant time x group interaction effects were found, h2p ¼ 0:04
(see Fig. 1). Post hoc tests revealed that individuals with
comorbid depression and those with comorbid depression
and anxiety had consistently higher PDSS-IE scores. Thus,
rates of change across treatment were similar across groups
and improvement in PDSS-IE was not a function of
comorbidity group status.
Treatment Response and Changes in Comorbidity
At pretreatment, 117 (45.7%) individuals had at least one
comorbid diagnosis of clinical severity. At posttreatment,
only 79 (30.9%) participants were assigned comorbid
diagnoses—a reduction that was statistically significant,
χ2(1, N=256)=49.47, p<0.001, ϕ=0.44. When examining
individual diagnoses, rates of GAD decreased significantly
from pretreatment to posttreatment: 25.4% to 14.1%, χ2
(1, N=256)=60.69, p<0.001, ϕ=0.49. However, this was
not true for rates of MDD, 16.4% to 9.0%, ϕ=0.30; social
Fig. 1 PDSS-IE scores (with standard errors) across treatment for
participants with no comorbidity, only anxiety comorbidity, only
depression comorbidity, and both anxiety and depression comorbidity.
PDSS-IE panic disorder severity scale—independent evaluator ver-
sion, Pre pretreatment, Post posttreatment
Table 3 Means (standard deviations) of pretreatment panic and
agoraphobia measures for COM and NOCOM groups
Measure COM (n=117) NOCOM (n=139) ES
PDSS-IE 15.45 (4.55) 12.50 (3.94)a 0.66
Agoraphobia Scale 20.99 (14.42) 14.78 (11.30)a 0.47
ASI 38.57 (10.31) 30.80 (12.21)a 0.65
WSAS 3.33 (1.82) 2.55 (1.59)a 0.45
COM = individuals with at least one comorbid diagnosis at
pretreatment, NOCOM = individuals with no comorbidity
ES effect size (Cohen’s d); PDSS-IE panic disorder severity scale—
independent evaluator version; ASI anxiety sensitivity index; WSAS
work and social adjustment scale
a indicates difference from COM at p<0.01
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phobia, 10.9% to 6.6%, ϕ=0.51; or specific phobia, 11.7%
to 7.4%, ϕ=0.45.
A 2 (response status: responder or nonresponder) × 2
(time: pre- or posttreatment) repeated measures ANOVA
was conducted with each SIGH-A and SIGH-D score as
dimensional measures of anxious and depressive symp-
toms, respectively. These analyses focused on response
status as a grouping variable because this variable was the
primary indicator of successful treatment, which would
allow us to determine the relationship of our measure of
treatment outcome to changes in comorbid symptoms. On
SIGH-A scores, there was a significant effect of time, F(1,
254)=102.76, p<0.001, h2p ¼ 0:29, and a small significant
group × time interaction, F(1, 254)=27.39, p<0.001,
h2p ¼ 0:10. The group effect was not significant (h2p ¼
0:01). As hypothesized, treatment responders showed
greater reductions on SIGH-A scores across treatment as
compared to nonresponders. Similarly, on the SIGH-D,
there was a small significant effect of time F(1, 254)=
51.55, p<0.001, h2p ¼ 0:17, and a small significant interac-
tion F(1, 254)=16.98, p<0.001, h2p ¼ 0:06. Again, res-
ponders showed greater reductions across treatment as
compared to nonresponders, although the group effect was
not significant (h2p ¼ 0:05).
Discussion
The results from our clinical trial provide support that a
structured CBT protocol for panic disorder is similarly
efficacious for individuals with and without common
comorbid anxiety and unipolar mood disorders. Further-
more, successful implementation of the protocol was
associated with reduction in symptoms (although not
necessarily diagnoses) of anxiety and depressive disorders
not specifically addressed in the treatment protocol. Rates
of comorbid GAD declined significantly from pre- to
posttreatment, and although rates of MDD, specific phobia,
and social phobia declined, these changes were not
significant. Not surprisingly, treatment responders showed
greater reductions on measures of anxiety and depression
across treatment, as compared to nonresponders.
Another important finding was that individuals with
comorbid depression (with or without comorbid anxiety)
showed similar improvement across treatment on a measure
of panic disorder and agoraphobia severity (PDSS-IE), as
compared to participants with only comorbid anxiety or no
comorbidity at all. These data contradict findings from
other studies suggesting that the presence of comorbid
depression is associated with worse outcome (Brown et al.
1995; Reif et al. 2000; Steketee et al. 2001), although
perhaps the smaller sample sizes in these studies may have
been related to the differential findings. Laberge et al.
(1993) found that depression was not associated with worse
outcome, despite depressed patients’ tendency to minimize
gains. Similarly, McLean et al. (1998) found no adverse
effects of comorbid depression when treating panic disor-
der. The results from our investigation provide support that
comorbid depression is not associated with worse outcome;
however, this rather restricted sample due to exclusionary
criteria (e.g., bipolar mood disorders) and non-assessment
of Axis II disorders make it difficult to draw strong
conclusions. Rates of comorbid MDD also decreased, but
this decrease did not reach statistical significance. This may
suggest that comorbid depressive disorders are somewhat
less “responsive” to CBT for panic disorder, as compared to
anxiety disorders such as GAD, or may be an artifact of a
somewhat smaller rate of comorbid MDD. Similarly, rates
of comorbid social phobia and specific phobia showed
improvement that also did not reach statistical significance.
Further exploration of the relationship of depression and
specific types of anxiety disorders to panic disorder
treatment is warranted.
One issue that has proven difficult to reconcile is
whether the presence of comorbidity is associated with
more severe symptoms of the principal disorder (Berkson
1946). The few studies examining this aspect of comorbid-
ity have yielded conflicting results. Brown et al. (1995)
found that individuals with panic disorder and at least one
additional diagnosis were rated as having more severe panic
symptoms than those without any additional diagnoses. In
addition, comorbid individuals evidenced higher ASI and
WSAS scores. However, Tsao et al. (1998) found no such
difference in their sample of panic disorder patients with
and without comorbidity (which may have been due to
relatively small sample size), although, in a follow-up
investigation, Tsao and colleagues (2002) reported that
patients with comorbidity reported significantly higher ASI
scores than those without comorbidity. Our study demon-
strated that COM individuals were rated as more severe on
all measures of panic disorder, and number of comorbid
diagnoses was significantly associated with measures of
panic disorder and agoraphobia severity. Given the variety
of measures used, and the fact that the data were taken from
both patients and independent evaluators, this finding
appears robust, at least with respect to the relationship
between anxiety and depression comorbidity and panic
disorder. Even more encouraging is that, despite having
more severe panic disorder symptoms at pretreatment,
individuals with comorbid anxiety and/or depression were
equally likely to respond to treatment as those without such
comorbid diagnoses, at least on categorical measures of
treatment response.
There are several possible mechanisms by which CBT for
panic disorder may be having an impact on comorbid
conditions, including 1) many of the skills taught in CBT for
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panic (e.g., monitoring, cognitive restructuring, and exposure)
are useful in coping with other emotional disorders and 2)
alleviating panic symptoms as a “cause” for other symptoms of
anxiety and depression will necessarily reduce the prevalence
and intensity of “secondary” comorbid disorders. A potentially
more interesting hypothesis is that CBT may be targeting a
broader problem experiencing and regulating emotions (see
Barlow et al. 2004; Campbell-Sills and Barlow 2007). CBT,
then, may serve to reduce the intensity of all emotional
experiences, rather than just panic symptoms.
There are several limitations of the current study worth
noting. First, due to the nature of the study, only patients
with a principal diagnosis of panic disorder were included. In
addition, we did not include an assessment of Axis II
disorders, which limits generalizability of the findings to
comorbid diagnoses outside of anxiety and mood disorders.
Study inclusionary criteria may have also restricted the
applicability of the findings to a more diverse patient
population. Replication of these findings is needed in more
diagnostically and ethnically diverse community and clinical
samples. Additionally, there was no control condition in the
current study (i.e., all patients received the same treatment),
so there can be no guarantee that treatment effects are
specifically related to CBT. Finally, the nature of the study
design precludes follow-up analyses to explore the relation-
ship of CBT for panic disorder to comorbidity over time.
Nonetheless, findings from the current study add to the
knowledge of panic disorder and comorbid anxiety and
depression in a number of important ways. These data
confirm findings that comorbidity does not necessarily
impede treatment for panic disorder, although highlight the
possibility of differential relationships between panic
disorder and specific comorbid anxiety and depressive
disorders. Further research exploring these differential
relationships is clearly warranted, particularly with more
generous inclusionary criteria, and the relationship of
comorbidity and treatment outcome for other disorders.
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